Effect of Jaeumgeonbi-Tang on Chronic Subjective Dizziness

• Status: Suspended
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to assess the safety and efficacy of JGT (Jaeumgeonbi-Tang). A randomized, double-blind, parallel-group, placebo-controlled clinical trial was conducted and changes in symptoms and quality of life of the patients were evaluated.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Korea Health Industry Development Institute

Criteria

[Inclusion Criteria]

• Chronic subjective dizziness patients, aged from 20 to 65

• DHI (Dizziness Handicap Inventory) score ≥ 24

• Those who can fully comprehend the general protocol of this study and voluntarily agree to participate

[Exclusion Criteria]

• Inner ear disease (benign paroxysmal positional vertigo, vestibular neuritis, Meniere's disease, etc.)

• Dizziness secondary to specific diseases such as hypoglycemia, recent stroke (within the last 6 months), or heart disease.

• Use of medications that could influence the result of the study (anticonvulsants, sedatives, antidepressants, sleeping pills, prostate medicine, Parkinson's drug, dementia drug, etc.)

• Pregnancy, breastfeeding, or plans of becoming pregnant

• Functional dyspepsia (persistent, recurring abdominal pain, or discomfort)

• Other allergic diseases

• Ineligibility for other reasons in the opinion of the research clinician (when the physician determines that there are significant physical or mental defects that the patient cannot understand and follow the protocol)